VERVE-102 is an experimental one-time gene-editing therapy designed to permanently lower bad LDL cholesterol by targeting the PCSK9 gene. Early clinical trial results showed significant and long-lasting cholesterol reductions after a single infusion, raising hopes that the treatment could someday reduce dependence on daily statins and transform heart disease prevention.